U101 Dysplastic Nevi for Dummies
DESCRIPTION
Management of dysplastic nevi remains controversial given the uncertainties surrounding their diagnosis and malignant potential. Recent data suggests that many dysplastic nevi are not necessarily obligate precursors to melanoma but are markers of melanoma risk. This session seeks to use the most up-to-date evidence to guide providers on how to counsel, manage, and follow patients with dysplastic nevi.
LEARNING OBJECTIVES
Examine the controversies and uncertainties surrounding the diagnosis of dysplastic nevi
Outline a management algorithm for dysplastic nevi based on the most recent data in the literature
Discuss new molecular techniques available to better characterize the malignant potential of dysplastic nevi
DIRECTOR
Elizabeth Gates Berry, MD, FAAD
SPEAKERS
Benjamin Stoff, MD, FAAD
Michael Tetzlaff, MD, PhD
DISCLOSURES
Elizabeth Gates Berry, MD, FAAD
Orlucent – Investigator(Grants/Research Funding);
Benjamin Stoff, MD, FAAD
No financial relationships exist with ineligible companies.
Michael Tetzlaff, MD, PhD
Merck – Other(Fees); Philogen S.p.A. – Advisory Board(Fees); Regeneron – Advisory Board(Honoraria);